| 초록 |
Recently, small interfering RNA (siRNA) has been recognizes as a potential drug for the treatment of human disease due to its target-specific gene silencing via RNA interference (RNAi) pathway. The siRNA therapeutics mainly depends on the successful delivery of siRNA molecules into the cytoplasm of target cells, However, siRNA shows poor pharmacological properties such as low serum stability, off-targeting effects, and innate immune responses, which present a significant challenge for clinical applications. In addition, the anionic, hydrophilicity, and stiff structures of siRNA make it difficult to cross the cell membrane for RNAi-mediated gene silencing. To achieve siRNA therapeutics, it is required urgently to develop a safe, stable, and efficient siRNA delivery systems. |
